196 related articles for article (PubMed ID: 8913840)
1. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
[TBL] [Abstract][Full Text] [Related]
2. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
3. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
4. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Macaulay VM; O'Byrne KJ; Saunders MP; Braybrooke JP; Long L; Gleeson F; Mason CS; Harris AL; Brown P; Talbot DC
Clin Cancer Res; 1999 Mar; 5(3):513-20. PubMed ID: 10100701
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.
Beattie GJ; Smyth JF
Clin Cancer Res; 1998 Aug; 4(8):1899-902. PubMed ID: 9717817
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
Parsons SL; Watson SA; Steele RJ
Eur J Surg Oncol; 1997 Dec; 23(6):526-31. PubMed ID: 9484924
[TBL] [Abstract][Full Text] [Related]
9. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
Brown PD
Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake bothrops asper.
Escalante T; Franceschi A; Rucavado A; Gutiérrez JM
Biochem Pharmacol; 2000 Jul; 60(2):269-74. PubMed ID: 10825472
[TBL] [Abstract][Full Text] [Related]
12. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
13. Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis.
Pollitt CC; Pass MA; Pollitt S
Equine Vet J Suppl; 1998 Sep; (26):119-24. PubMed ID: 9932102
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
Talbot DC; Brown PD
Eur J Cancer; 1996 Dec; 32A(14):2528-33. PubMed ID: 9059343
[No Abstract] [Full Text] [Related]
15. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
[TBL] [Abstract][Full Text] [Related]
16. Influence of the matrix metalloproteinase inhibitor batimastat (BB-94) on periodontal bone destruction in Sprague-Dawley rats.
Björnsson MJ; Havemose-Poulsen A; Stoltze K; Holmstrup P
J Periodontal Res; 2004 Aug; 39(4):269-74. PubMed ID: 15206921
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
Corbel M; Caulet-Maugendre S; Germain N; Molet S; Lagente V; Boichot E
J Pathol; 2001 Apr; 193(4):538-45. PubMed ID: 11276015
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Rasmussen HS; McCann PP
Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
[TBL] [Abstract][Full Text] [Related]
19. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
